Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 5
---
 -  
     -  
     21 
  
    Purchases of shares of Common Stock under Keystone ELOC, net of issuance costs of $124,131 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     75,064  
     8  
     481,963  
     -  
     -  
     481,971 
  
    Issuance of shares of Common Stock upon conversion of Series B Preferred Stock 
     -  
     -  
     (198) 
     (158,147) 
     -  
     -  
     -  
     -  
     42,258  
     4  
     158,143  
     -  
     -  
     - 
  
    Issuance of shares of Common Stock upon conversion of Series C Preferred Stock 
     -  
     -  
     -  
     -  
     (2,477) 
     (935,208) 
     -  
        
     808,444  
     81  
     935,127  
     -  
     -  
     - 
  
    Issuance of series D Preferred Stock for cash and equity securities, net of issuance costs of $362,220 
     -  
     -  
     -  
     -  
     -  
     -  
     9,503  
     7,240,180  
     -  
     -  
     (4,500,000) 
     -  
     -  
     2,740,180 
  
    Stock-based inducement expense related to conversion of Series C Preferred Stock 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     707,300  
     -  
     -  
     707,300 
  
    Stock-based compensation 
     -